A detailed history of Efg Asset Management (North America) Corp. transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Efg Asset Management (North America) Corp. holds 33,689 shares of BPMC stock, worth $3.05 Million. This represents 0.53% of its overall portfolio holdings.

Number of Shares
33,689
Previous 27,884 20.82%
Holding current value
$3.05 Million
Previous $3.01 Million 3.63%
% of portfolio
0.53%
Previous 0.53%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$84.1 - $120.5 $488,200 - $699,502
5,805 Added 20.82%
33,689 $3.11 Million
Q2 2024

Jul 25, 2024

BUY
$85.18 - $108.78 $11,243 - $14,358
132 Added 0.48%
27,884 $3.01 Million
Q1 2024

May 13, 2024

BUY
$73.17 - $99.79 $114,584 - $156,271
1,566 Added 5.98%
27,752 $2.63 Million
Q4 2023

Feb 08, 2024

SELL
$43.96 - $92.84 $28,617 - $60,438
-651 Reduced 2.43%
26,186 $2.42 Million
Q3 2023

Nov 02, 2023

SELL
$46.9 - $66.0 $2.97 Million - $4.18 Million
-63,287 Reduced 70.22%
26,837 $1.35 Million
Q2 2023

Jul 28, 2023

SELL
$42.2 - $66.37 $844,717 - $1.33 Million
-20,017 Reduced 18.17%
90,124 $5.7 Million
Q1 2023

Apr 27, 2023

SELL
$37.97 - $50.0 $27,034 - $35,600
-712 Reduced 0.64%
110,141 $4.96 Million
Q4 2022

Feb 03, 2023

SELL
$41.06 - $66.48 $170,029 - $275,293
-4,141 Reduced 3.6%
110,853 $4.86 Million
Q3 2022

Oct 28, 2022

SELL
$49.93 - $77.7 $771,917 - $1.2 Million
-15,460 Reduced 11.85%
114,994 $7.58 Million
Q2 2022

Aug 04, 2022

SELL
$45.23 - $70.15 $282,099 - $437,525
-6,237 Reduced 4.56%
130,454 $6.59 Million
Q1 2022

Apr 26, 2022

BUY
$54.1 - $110.08 $1.3 Million - $2.64 Million
23,976 Added 21.27%
136,691 $8.73 Million
Q4 2021

Feb 18, 2022

BUY
$94.25 - $115.99 $10.6 Million - $13.1 Million
112,715 New
112,715 $12.1 Million

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.4B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Efg Asset Management (North America) Corp. Portfolio

Follow Efg Asset Management (North America) Corp. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Efg Asset Management (North America) Corp., based on Form 13F filings with the SEC.

News

Stay updated on Efg Asset Management (North America) Corp. with notifications on news.